Erschienen in:
01.08.2005
Radiofrequency ablation of renal cell carcinoma
verfasst von:
J. D. Schiller, D. A. Gervais, P. R. Mueller
Erschienen in:
Abdominal Radiology
|
Ausgabe 4/2005
Einloggen, um Zugang zu erhalten
Excerpt
There are more than 31,000 new cases of renal cell carcinoma (RCC) each year in the United States, with 12,100 deaths every year [
1]. The incidence of RCC has been increasing each year, attributed in large part to the increase in incidental cases of renal masses detected with the widespread use of cross-sectional imaging [
1,
2,
3]. These incidental lesions are subsequently detected at an increasingly smaller size, lower clinical stage, and with more favorable histologic features [
3,
4,
5,
6]. Thus, these lesions that are incidentally detected are associated with better survival outcomes than symptomatic lesions. The overall 5-year survival rate for patients with symptomatic lesions was 53% as opposed to 85% for incidental lesions as reported by Sweeny et al. [
7]. The treatment of RCC has evolved over the past 15 to 20 years and will continue to evolve with the advent of new percutaneous therapies. …
